Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis

[1]  B. Joffe,et al.  Insulin resistance and impaired beta cell function in rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[2]  M. Cutolo,et al.  Effects of Anti‐TNF‐α Treatment on Lipid Profile in Patients with Active Rheumatoid Arthritis , 2006 .

[3]  A. Drosos,et al.  Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. , 2006, The Journal of rheumatology.

[4]  D. Borderie,et al.  Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[5]  O. Johnson,et al.  Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long‐term infliximab therapy , 2006, Scandinavian journal of rheumatology.

[6]  C. Turesson,et al.  Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. , 2005, The Journal of rheumatology.

[7]  B. Dijkmans,et al.  Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. , 2005, The Journal of rheumatology.

[8]  A. Drosos,et al.  Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis , 2004, Annals of the rheumatic diseases.

[9]  M. Netea,et al.  Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis , 2004, Annals of the rheumatic diseases.

[10]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[11]  I. McInnes,et al.  Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. , 2003, Circulation.

[12]  E. Cauza,et al.  Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. , 2002, Wiener klinische Wochenschrift.

[13]  B. Joffe,et al.  Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study , 2002, Arthritis research.

[14]  G. McColl,et al.  Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? , 2002, Arthritis and rheumatism.

[15]  J. Després,et al.  The Dense LDL Phenotype: Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men , 1996, Diabetes Care.

[16]  B. Spiegelman,et al.  IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Resistance , 1996, Science.

[17]  E. Shiloni,et al.  Mechanism of the hypertriglyceridemia induced by tumor necrosis factor administration to rats. , 1989, Biochimica et biophysica acta.

[18]  M. Cutolo,et al.  Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. , 2006, Annals of the New York Academy of Sciences.

[19]  M. González-Gay,et al.  Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. , 2006, Clinical and experimental rheumatology.

[20]  R. Maini,et al.  The Role of Cytokines in Rheumatoid Arthritis , 1996, Journal of the Royal College of Physicians of London.